The burden of varicella in Germany: Potential risks and economic impact

European Journal of Health Economics

Volumn 5, Issue 1, 2004, Pages 46-53

  Banz, Kurt ^a   Wagenpfeil, Stefan ^b   Neiss, Albrecht ^b   Hammerschmidt, Thomas ^c   Wutzler, Peter ^d  

^a Outcomes International   (Switzerland)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c GLAXOSMITHKLINE   (Germany)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Chickenpox; Complications; Cost of illness; Germany; Varicella

Indexed keywords

CHICKENPOX VACCINE;

ARTICLE; CHICKENPOX; CHILDHOOD DISEASE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE COURSE; DISEASE MODEL; GERMANY; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HEALTH ECONOMICS; HUMAN; MORALITY; MORBIDITY; NEUROLOGICAL COMPLICATION; OTITIS MEDIA; OUTPATIENT CARE; PNEUMONIA; PRIORITY JOURNAL; VACCINATION;

ADOLESCENT; ADULT; CHICKENPOX; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; GERMANY; HEALTH CARE COSTS; HUMANS; INFANT; INFANT, NEWBORN; RETROSPECTIVE STUDIES;

EID: 1542284170     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-003-0200-7     Document Type: Article

References (41)

1. Preblud SR, Orenstein WA, Kenneth JB (1984) Varicella: clinical manifestations, epidemiology and health impact in children. Pediatr Infect Dis 3:505-509
2. Anonymous (2000) Verschreibungsindex für Pharmazeutika. IMS Health: Frankfurt
3. Fairley CK, Miller E (1996) Varicella-zoster virus epidemiology - a changing scene? J Infect Dis 174[Suppl. 3]:S314-319
4. Wutzler P, Färber I, Wagenpfeil S, Bisanz H, Tischer A (2002) Seroprevalence of varicella-zoster virus in the German population. Vaccine 20:121-124
5. Choo PW, Donahue JG, Manson JE, Platt R (1995) The epidemiology of varicella and its complications. J Infect Dis 172:706-712
6. Fleisher G, Henry W, McSorley M, Arbeter A, Plotkin S (1981) Life-threatening complications of varicella. Am J Dis Child 135:896-899
7. Guess HA, Broughton DD, Melton LJ, Kurland LT (1986) Population-based studies of varicella complications. Pediatrics 78[Suppl.]:723-727
8. National Committee on Immunization (1999) Statement on recommended use of varicella virus vaccine. Can Commun Dis Rep 25:1-16
9. Boelle PY, Hanslik T (2002) Varicella in non-immune persons: incidence, hospitalization and mortality rates. Epidemiol Infect 129:599-606
10. Galil K, Brown C, Lin F, Seward J (2002) Hospitalization for varicella in the United States, 1988-1999. Pediatr Infect Dis J 21:931-934
11. Jaeggi A, Zurbruegg RP, Aebi C (1998) Complications of varicella in a defined central European population. Arch Dis Child 79:472-477
12. Centers for Disease Control and Prevention (CDC) (2001) Epidemiology and prevention of vaccine-preventable diseases. The pink book,. 6th edn. CDC: Atlanta
13. Preblud SR (1986) Varicella: complications and costs. Pediatrics 78[Suppl.]:728-735
14. Drwal-Klein LA, O'Donnovan CA (1993) Varicella in pediatric patients. Ann Pharmacother 27:938-949
15. Enders G, Miller E, Cradock-Watson J, Bolley I, Ridehalgh M (1994) Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet 343:1548-1551
16. Pastuszak AL, Levy M, Schick B, Zuber C, Feldkamp M, Gladstone J, Bar-Levy F, Jackson E, Donnenfeld A Meschino W (1994) Outcome after maternal varicella infection in the first 20 weeks of pregnancy. N Engl J Med 330:901-905
17. Ellis ME, Neal KR, Webb AK (1987) Is smoking a risk factor for pneumonia in adults with chickenpox? BMJ 294:1002
18. Centers for Disease Control and Prevention (1996) Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 45:1-36
19. Meyer PA, Seward JF, Jumaan AO (2000) Varicella mortality: trends before licensure in the United States, 1970-1994. J Infect Dis 182:383-390
20. Rawson H, Crampin A, Noah N (2001) Deaths from chickenpox in England and Wales 1995-7: analysis o routine mortality data. BMJ 323:1091-1093
21. Ferson MJ, Shen, WL, Stark A (1998) Direct and indirect costs of chickenpox in young children. J Paediatr Child Health 34:18-21
22. Law B, Fitzsimon C, Ford-Jones L, MacDonald N, Dery P, Vaudry W, Mills E, Halperin S, Michaliszyn A, Riviere M (1999) Cost of chickenpox in Canada. I. Cost of uncomplicated cases. Pediatrics 104:1-6
23. Law B, Fitzsimon C, Ford-Jones L, McCormick J, Rivière M (1999) Cost of chickenpox in Canada. II. Cost of complicated cases and total economic impact. Pediatrics 104:7-14
24. Wagenpfeil S, Neiss A, Banz K, Wutzler P (2003) Empirical data on the varicella situation in Germany for vaccination decisions. Clin Microbiol Infect (in press)
25. Banz K, Wagenpfeil S, Neiss A, Goertz A, Staginnus U, Vollmar J, Wutzler P (2003) The cost-effectiveness of routine childhood varicella vaccination in Germany. Vaccine 21:1256-1267
26. Halloran ME, Cochi SL, Lieu TA, Wharton M, Fehrs L (1994) Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am J Epidemiol 140:81-104
27. Halloran ME (1996) Epidemiologic effects of varicella vaccination. Infect Dis Clin North Am 10:631-655
28. Statistisches Bundesamt (2000) Statistisches Jahrbuch für die Bundesrepublik Deutschland 2000. Metzler-Poeschel: Stuttgart
29. Centres for Disease Control (eds.) (2003) Epidemiology and prevention of vaccine-preventable diseases. The pink book, 7th edn. Public Health Foundation: Waldorf
30. Wezel H, Liebhold R (2000) Einheitlicher Bewertungsmaßstab für ärztliche Leistungen, 2000. Handkommentar BMÄ, E-GO und GOÄ. Asgard: St. Augustin
31. Bundesministerium für Gesundheit (2000) Daten des Gesundheitswesens 1999. Nomos: Baden-Baden
32. Koopmanschap MA, Rutten F (1996) A practical guide for calculating indirect costs of disease. Pharmacoeconomics 10:460-466
33. Gold MR, Siegel JE, Russel LB, Weinstein MC (1996) Cost-effectiveness in health and medicine. Oxford University Press: New York
34. Institut der Deutschen Wirtschaft (1999) Zahlen zur wirtschaftlichen Entwicklung der Bundesrepublik Deutschland 1999. Deutscher Instituts-Verlag: Cologne
35. Sozialgesetzbuch (2002) SGB V, Gesetzliche Krankenversicherung. Haarfeld: Essen
36. Hammerschmidt T, Goertz A, Wagenpfeil S, Neiss A, Wutzler P, Banz K (2003) Validation of health economic models: the example of EVITA. Value Health 6:551-559
37. Ratner AJ (2002) Varicella-related hospitalizations in the vaccine era. Pediatric Infect Dis J 21:927-930
38. Chant KG, Sullivan EA, Burgess MA, Ferson MJ, Forrest JM, Baird LM, Tudehope DI, Tilse M (1998) Varicella-zoster infection in Australia. Aust N Z J Public Health 22:413-418
39. Gray GC, Palinkas LA, Kelley PW (1990) Increasing incidence of varicella hospitalisations in United States army and navy personnel: are today's teenagers more susceptible? Should recruits be vaccinated? Pediatrics 86:867-873
40. Lieu TA, Cochi SL, Black SB, Halloran E, Shinefield HR, Holmes SJ, Wharton M, Washington E (1994) Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 271:375-381
41. Seward JF, Watson BM, Peterson CJ, Mascola L, Pelosi JW (2002) Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 287:606-611